Bictegravir/lenacapavir (Bixlenvo) vs VH4524184

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

Bictegravir/lenacapavir (Bixlenvo)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Partial signal

NCT05502341 · Phase 2/3 · active, not recruiting

This was a randomized, active-controlled trial in 557 people in its Phase 3 part, but it was open-label, so participants and investigators knew which treatment each person received. Its primary endpoint, the proportion with detectable HIV-1 RNA at week 48, is an objective laboratory measure, and bictegravir/lenacapavir met the non-inferiority goal against continued complex regimens.

Next expected readout: July 2028 · NCT07908446 (registry estimate)

Reported efficacy

Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm; Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). (met)

Result source: NCT05502341

VH4524184

Developed by ViiV Healthcare

Phase 2 in HIVsmall molecule
Partial signal

NCT06214052 · Phase 2 · completed

The study was randomized and double-blind with matching placebo, but it was very small, with 6, 6, and 7 participants receiving VH4524184 doses and only 3 receiving placebo. Its primary endpoint was a surrogate measure of plasma HIV-1 RNA change, and although the reported mean changes favored the medium and high doses, statistical significance was not reported.

Next expected readout: October 2027 · NCT07202546 (registry estimate)

Reported efficacy

Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): VH4524184 Dose 1 -1.17 Copies per milliliter (copies/mL) (Standard Deviation 0.46) | VH4524184 Dose 2 -2.15 Copies per milliliter (copies/mL) (Standard Deviation 0.254) | VH4524184 Dose 3 -2.31 Copies per milliliter (copies/mL) (Standard Deviation 0.463) vs Placebo -0.28 Copies per milliliter (copies/mL) (Standard Deviation 0.37) (unclear)

Result source: NCT06214052

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBictegravir/​lenacapavir (Bixlenvo)VH4524184
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT06532656—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06532656—Not reported
CD4 count, change (week 48)—Trial running · NCT06532656—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
VH4524184
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
VH4524184
—Not reported

CD4 count, change (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
VH4524184
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Bictegravir/lenacapavir (Bixlenvo)
Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). NCT05502341 · Phase 2/3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Bictegravir/lenacapavir (Bixlenvo): 0 of 4 rows · VH4524184: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricVH4524184
Dropout rate
0%Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
show 8 more results
—Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
Discontinued due to AEs
—Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
show 8 more results
—Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
Serious AEs
—Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
show 8 more results
0%Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
Most frequent reported AEs
Dose 1
abdominal distension 16.7% (placebo 0%)
acute sinusitis 16.7% (placebo 0%)
dermatitis 16.7% (placebo 0%)
NCT06214052 · Phase 2 · combination · HIV · phase 2
show 5 more results
Dose 1
dermatitis 16.7% (placebo 0%)
diarrhoea 16.7% (placebo 33.3%)
abdominal distension 0% (placebo 0%)
NCT06214052 · Phase 2 · combination · HIV · phase 2
Dose 2
alanine aminotransferase increased 16.7% (placebo 0%)
gastroenteritis 16.7% (placebo 33.3%)
hypertension 16.7% (placebo 0%)
NCT06214052 · Phase 2 · combination · HIV · phase 2
Dose 2
amylase increased 16.7% (placebo 0%)
fatigue 16.7% (placebo 0%)
lipase increased 16.7% (placebo 0%)
NCT06214052 · Phase 2 · combination · HIV · phase 2
Dose 3
abdominal distension 14.3% (placebo 0%)
diarrhoea 14.3% (placebo 33.3%)
dyspepsia 14.3% (placebo 0%)
NCT06214052 · Phase 2 · combination · HIV · phase 2
Dose 3
dizziness 14.3% (placebo 0%)
headache 14.3% (placebo 66.7%)
influenza like illness 14.3% (placebo 0%)
NCT06214052 · Phase 2 · combination · HIV · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

VH4524184

HIV-1 RNA -1.17 vs -0.28 placebo copies/mL @ 1.43wkDose 1
absolute change · copies/mL
NCT06214052 · Phase 2 · combination · HIV · phase 2
show 2 more results
-2.15 vs -0.28 placebo copies/mL @ 1.43wkDose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
-2.31 vs -0.28 placebo copies/mL @ 1.43wkDose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
CD4+ 131.333 vs 63.667 placebo cells/uL @ 1.43wkDose 1
absolute change · cells/uL
NCT06214052 · Phase 2 · combination · HIV · phase 2
show 2 more results
68.667 vs 63.667 placebo cells/uL @ 1.43wkDose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
47 vs 63.667 placebo cells/uL @ 1.43wkDose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir/lenacapavir (Bixlenvo)'s landscape · VH4524184's landscape